Incyte launches award programme recognising innovation in GVHD community

have a devastating impact on the lives of patients,” said Barry Flannelly, executive vice president and general manager, US, Incyte. ... Through the Incyte Ingenuity Award, we hope to spark creativity and innovation, which we expect to result in

Incyte’s JAK inhibitor cream clears second eczema trial

Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... Incyte has said it intends to market ruxolitinib cream itself in

Novartis pulls ahead of Merck in MET-positive lung cancer race

Capmatinib – originally developed by Incyte and licensed to Novartis in 2009 – has been submitted for approval in the US for metastatic MET exon14 skipping-mutated NSCLC, a form of lung cancer

Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

to patients and the clinical community around the world,” said Hervé Hoppenot, CEO of Incyte. ... Under the terms of the deal, Incyte is paying MorphoSys $750m upfront, as well as making an equity investment worth $150m in the company.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]